[Dr.Vad]

Младшой собрат триметазидина - ранолазин тоже показал нулевой результат при лечении ОКС:

The Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes Thrombolysis in MI-36 (MERLIN TIMI-36) was a multinational, double-blind, randomized, placebo-controlled trial designed to evaluate the efficacy and safety of ranolazine during acute and long-term treatment in around 6500 patients with NSTE ACS treated with standard therapy.
The results show that the study drug ranolazine failed to reduce time to cardiovascular death, myocardial infarction, and/or recurrent ischemia compared with placebo in patients with non-ST segment elevation acute coronary syndrome.

Однако, учитывая наличие отсутствия эксцессов смертности и аритмий, препарат похоже может получить статус "американского предуктала":

However, the study sponsor CV Therapeutics reports that there was no adverse trend in death or arrhythmias in patients on ranolazine. If these findings are borne out in the full results, they could support approval of ranolazine as first-line chronic angina therapy, as agreed in a Special Protocol Assessment with the US Food and Drug Administration.

Ranolazine is currently indicated for the second-line treatment of chronic angina, in combination with amlodipine, beta-blockers, or nitrates, in patients who have not achieved an adequate response with other anti-anginal drugs. Concerns that the drug could lead to arrhythmias by prolonging the QT interval have restricted its use in this way.

По материалам ACC 2007 congress in New Orleans, Louisiana